Home > Blog > Successful dmc services for complex hematologic cancer trial

Successful DMC Services for Complex Hematologic Cancer Trial

Clinical Trial Regulations Regulatory Consulting Regulatory Submissions

Learn how Veristat's expert biostatistics team worked with a longstanding global biopharma sponsor to navigate complex Data Monitoring Committee (DMC) requirements for a challenging hematologic cancer trial. Collaborative efforts led to successful trial progression and maintained data integrity throughout all study phases.

A global biopharmaceutical company specializing in cell therapies contacted  Veristat for support with an ongoing Phase 3 clinical trial for the treatment of relapsed refractory multiple myeloma. The study aimed to establish the efficacy and safety of their novel therapy in over 500 patients with this aggressive form of blood cancer.

In this piece, learn how Veristat's multidisciplinary team was able to work with the sponsor to solve challenges across numerous areas including:

  • Complex statistical design and analysis requirements
  • Intensive DMC reporting and communication needs
  • Multiple interim analyses and sample size re-estimation

DOWNLOAD

 

2 min read

SCDM ANNUAL CONFERENCE 2026

Jul 24, 2026  Veristat Events

Meet Veristat at the SCDM Annual ConferenceSeptember 14–17, 2026 – Raleigh, North Carolina

Advancing Clinical Data...

2 min read

Connect with Veristat at Bio International Convention 2026

Jun 15, 2026  Veristat Events

June 22-25, 2026 – San Diego, CA

🌎 Bringing the Global Biopharma Community Together

We’re delighted to be attending...